About Ardelyx, Inc.
Ardelyx is a publicly traded biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA® (tenapanor) is available in the United States. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx has a Phase 2 potassium secretagogue program, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.
|
|
|
11-50 employees
View all Ardelyx, Inc. employees
|
|
Biotechnology
|
|
400 Fifth Avenue, 210, Waltham, MA 02451, US
|
|
2007
|
Ardelyx, Inc. Alternatives
Frequently Asked Questions about Ardelyx, Inc.
Veronica David is the CEO of Ardelyx, Inc..
The decision makers in Ardelyx, Inc. are Dan Olmstead, David Rosenbaum, Elizabeth Grammer, etc. Click to Find Ardelyx, Inc. decision makers emails.
Ardelyx, Inc. Staff Directory
Search Ardelyx, Inc. Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
